The National Parkinson Foundation and Melbourne's Global Kinetics Corporation have announced a randomised controlled trial using new technology which hopes to provide better information to physicians in the treatment of Parkinson's disease.

The trial will study the impact of continuous objective movement in patients with Parkinson's disease, helping physicians to improve treatment decisions of patients with the disease.

The Parkinson's KinetiGraphTM (PKGTM) is a mobile health technology developed by Melbourne based medtech company Global Kinetics Corporation to accurately measure movement in patients with Parkinson's and other movement disorders.

The PKGTM is a wrist-worn device that automatically records motion data over a period of 6 days.  This information can then be downloaded by doctors and trends and changes identified, allowing them to make important considerations in diagnosis and treatments.  The device can also alert patients when it's time to take medication.

The clinical research project will involve over 400 Parkinson's patients and will be a multi-centre randomised controlled trial. 

The trial forms a part of the National Parkinson's Foundation Parkinson's Outcomes Project Registry Study, which has grown to become the largest clinical study of Parkinson's disease in the world involving nearly 9,000 patients and over 20 leading movement disorder specialist centres.

The PKGTM was developed by neurologists at the world-renowned Florey Institute of Neurosciences and Mental Health in Melbourne, and Global Kinetics Corporation was formed in 2007 to commercialise the product.

Victoria's medical devices sector is backed by strong infrastructure, world-leading research institutes and a Government committed to supporting innovation. More than 1000 medtech companies are located in the State employing between 4,000 to 5,000 people.